Back to Journals » Therapeutics and Clinical Risk Management » Assessment and Management of Cardiovascular Risk
Therapeutics and Clinical Risk Management
- View all (2615)
- Volume 22, 2026 (59)
- Volume 21, 2025 (162)
- Volume 20, 2024 (86)
- Volume 19, 2023 (91)
- Volume 18, 2022 (104)
- Volume 17, 2021 (134)
- Volume 16, 2020 (134)
- Volume 15, 2019 (154)
- Volume 14, 2018 (271)
- Volume 13, 2017 (188)
- Volume 12, 2016 (217)
- Volume 11, 2015 (210)
- Volume 10, 2014 (113)
- Volume 9, 2013 (57)
- Volume 8, 2012 (47)
- Volume 7, 2011 (59)
- Volume 6, 2010 (66)
- Volume 5, 2009 (102)
- Volume 4, 2008 (148)
- Volume 3, 2007 (126)
- Volume 2, 2006 (47)
- Volume 1, 2005 (40)
Journal Articles:
- Older and newer players in the therapeutics of Cardio-Kidney-Metabolic syndrome (1)
- Machine Learning in the Realm of Therapeutics and Clinical Risk Management (1)
- Lymphoproliferation at the crossroad between hematology and immunology: molecular and clinical implications (1)
- Anticholinergic Therapies for the Treatment of Asthma (7)
Assessment and Management of Cardiovascular Risk
Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality worldwide, necessitating a comprehensive understanding of cardiovascular risk factors and the development of effective prevention and management strategies. This Article Collection aims to explore the multifaceted nature of cardiovascular risk, encompassing traditional factors such as hypertension, dyslipidemia, and diabetes, alongside emerging risk factors, including inflammatory markers, genetic predispositions, and lifestyle influences. The goal is to highlight innovative approaches to risk assessment, early detection, and tailored therapeutic strategies that can optimize cardiovascular health outcomes.